Gainers
Evelo Biosciences, Inc. (NASDAQ: EVLO) jumped 147.9% to $0.2479. Evelo Biosciences shares dropped 33% on Wednesday after the company announced top-line data from the fourth cohort of its EDP1815 Phase 2 trial, in which the primary endpoint was not met.
ContraFect Corporation (NASDAQ: CFRX) gained 87% to $2.4693. ContraFect said first patient was dosed in the Phase 1b/2 study of exebacase in patients with chronic prosthetic joint infections of the knee.
Hillstream BioPharma, Inc. (NASDAQ: HILS) jumped 56% to $1.10.
TOP Financial Group Limited (NASDAQ: TOP) rose 53.7% to $10.33.
U Power Limited (NASDAQ: UCAR) climbed 33.5% to $5.45 after declining around 27% on Wednesday.
Atomera Incorporated (NASDAQ: ATOM) shares gained 23.6% to $6.45 after the company posted results for its first quarter. The company announced the execution of a commercial license agreement with STMicroelectronics (ST) that enables the latter to install Atomera's Mears Silicon Technology into its facilities.
OMNIQ Corp. (NASDAQ: OMQS) climbed 20.8% to $5.47.
Vapotherm, Inc. (NYSE: VAPO) rose 19.4% to $0.5001.
Helen of Troy Limited (NASDAQ: HELE) shares gained 19.1% to $97.39 after the company announced better-than-expected Q4 results.
Nuburu, Inc. (NYSE: BURU) gained 19% to $1.13.
Bel Fuse Inc. (NASDAQ: BELFB) rose 18.3% to $36.25 following better-than-expected quarterly results.
Immuron Limited (NASDAQ: IMRN) gained 16.4% to $2.23.
CXApp Inc. (NASDAQ: CXAI) climbed 16% to $10.74.
Mainz Biomed N.V. (NASDAQ: MYNZ) gained 15.6% to $3.92.
Accuray Incorporated (NASDAQ: ARAY) jumped 15% to $3.1050 after the company reported better-than-expected Q3 EPS and sales results.
LianBio (NASDAQ: LIAN) rose 14.7% to $2.26. LianBio announced topline results from the Phase 3 EXPLORER-CN trial investigating mavacamten for Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
Meta Platforms, Inc. (NASDAQ: META) climbed 14.3% to $239.64 as the company reported better-than-expected Q1 results and also announced an increase in active users.
Immix Biopharma, Inc. (NASDAQ: IMMX) gained 14.1% to $2.13 after ...
Benzinga